Cadila Pharma appoints Hemant Kumar as President - Supply Chain & Procurement
Cadila Pharma has appointed Hemant Kumar as President - Supply Chain & Procurement at the company.
Hemant shared the update via LinkedIn, stating, "I’m happy to share that I’m starting a new position as President - Supply Chain & Procurement at Cadila Pharmaceuticals Limited!"
With over 31 years of experience in global supply chain management, Hemant brings a wealth of expertise across Indian and international operations. He led various projects on SAP, MRP, APO and BPR/Simplification in SCM with Accenture, Bristlecone, BCG, Mckinsey & SAP. His professional journey has taken him from a Management Trainee to strategic leadership roles in different functions in Ranbaxy. This has also helped him transform into an expert in terms of systems/processes for all Backend operations comprising Supply Chain/Scheduling/Procurement/Logistics & Technical functions i.e. Mfg./Quality/Regulatory/Development with strong people management & leadership skills. He was also a Part of CEO & MDs office, working for Transformation & Business consulting Function on important Global Initiatives.
At Ranbaxy, Hemant headed the end-to-end Global Supply Chain Function for dosage forms and APIs, for captive consumption / Global Markets, overseeing warehousing functions for API manufacturing. He also played a role in the Sun-Ranbaxy integration team for SCM, later leading Central Planning function for India/Emerging markets/LL Ops & Consumer healthcare.
Read also: Cadila Pharma unveils quadrivalent influenza vaccine Cadiflu Tetra
Hemant also held the position of Vice President & Head – Regional Supply Chain and Logistics at Mylan Laboratories. His previous company before joining Cadila was Glenmark Pharma Mumbai.
Read also: Cadila Pharma unveils advanced pharmaceutical warehouse
Cadila Pharmaceuticals Ltd. is the largest privately-held pharmaceutical companies in India. Over the past seven decades, the Company has been developing and manufacturing medicines for patients around the world.
Read also: Cadila Pharma unveils quadrivalent influenza vaccine Cadiflu Tetra
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.